{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:45:58Z","timestamp":1793234758439,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD), the most common inflammatory skin disorder, carries a significant public health burden. Many patients with moderate-to-severe AD are unable to achieve adequate disease control with topical treatment and require treatment with oral immunosuppressants or monoclonal antibody injections. A continued unmet need for a safe, effective and easy-to-use oral drug exists. AD has a complex pathophysiology, including adaptive- and innate-dependent mechanisms, some of which involve Bruton tyrosine kinase (BTK). Rilzabrutinib is an oral, selective and reversible covalent BTK inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of rilzabrutinib in patients with moderate-to-severe AD and inadequate response or intolerance to topical corticosteroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible adults were enrolled in two staggered dose-regimen cohorts: 800\u2005mg daily (400\u2005mg twice daily) or 1200\u2005mg daily (400\u2005mg three times daily) and randomized 3 : 2 to receive rilzabrutinib or placebo for 16 weeks. The primary efficacy endpoint was percentage change in Eczema Area and Severity Index (EASI) score from baseline to week 16. Key secondary endpoints included the proportion of participants at week 16 achieving an Investigator\u2019s Global Assessment score of 0 or 1, achieving EASI 75 and with a reduction in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) of \u2265 4 from baseline. Safety was measured by recording adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary endpoint did not reach statistical significance [least squares mean difference vs. placebo: 800\u2005mg \u20136.3% (P = 0.62); 1200\u2005mg \u20133.9% (P = 0.67)]. The key secondary endpoints also did not demonstrate significant improvements with rilzabrutinib vs. placebo. However, a rapid improvement in absolute and relative change in weekly average of the daily PP-NRS was demonstrated with rilzabrutinib. Rilzabrutinib was well tolerated. Treatment-emergent AEs (TEAEs) were mostly mild, with a low incidence of serious AEs. TEAEs occurring at a higher frequency with rilzabrutinib than with placebo included nausea and diarrhoea. AEs associated with previous generations of BTK inhibitors were not seen with rilzabrutinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study did not meet its primary endpoint. However, consistent results favouring rilzabrutinib with regard to itch response were observed. These findings also highlight the acceptable safety profile of rilzabrutinib vs. the AEs associated with other BTK inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf156","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:45:38Z","timestamp":1746175538000},"page":"424-433","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0831-2151","authenticated-orcid":false,"given":"Leon","family":"Kircik","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Fachklinik Bad Bentheim , Bad Bentheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Valenzuela","sequence":"additional","affiliation":[{"name":"University of Chile and Probity Medical Research , Santiago ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mikol","sequence":"additional","affiliation":[{"name":"Sanofi , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaowei","family":"Nian","sequence":"additional","affiliation":[{"name":"Sanofi , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda","family":"Mannent","sequence":"additional","affiliation":[{"name":"Sanofi , Gentilly ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Baret-Cormel","sequence":"additional","affiliation":[{"name":"Sanofi , Gentilly ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"2025081809374412200_ljaf156-B1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","article-title":"Atopic dermatitis","volume":"22","author":"Bieber","year":"2010","journal-title":"Ann Dermatol"},{"key":"2025081809374412200_ljaf156-B2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025081809374412200_ljaf156-B3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"2025081809374412200_ljaf156-B4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1152\/physrev.00017.2019","article-title":"Physiology and pathophysiology of itch","volume":"100","author":"Cevikbas","year":"2020","journal-title":"Physiol Rev"},{"key":"2025081809374412200_ljaf156-B5","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N Engl J Med"},{"key":"2025081809374412200_ljaf156-B6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13555-023-01081-0","article-title":"Cutaneous components leading to pruritus, pain, and neurosensitivity in atopic dermatitis: a narrative review","volume":"14","author":"St\u00e4nder","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025081809374412200_ljaf156-B7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s41687-024-00764-2","article-title":"Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale","volume":"8","author":"Rams","year":"2024","journal-title":"J Patient Rep Outcomes"},{"key":"2025081809374412200_ljaf156-B8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2147\/CCID.S289716","article-title":"Current clinical options for the management of itch in atopic dermatitis","volume":"14","author":"Lipman","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025081809374412200_ljaf156-B9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025081809374412200_ljaf156-B10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp Dermatol"},{"key":"2025081809374412200_ljaf156-B11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.mcna.2021.04.007","article-title":"Approach to the patient with chronic pruritus","volume":"105","author":"Lipman","year":"2021","journal-title":"Med Clin North Am"},{"key":"2025081809374412200_ljaf156-B12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.sder.2011.04.008","article-title":"Topical therapies for pruritus","volume":"30","author":"Elmariah","year":"2011","journal-title":"Semin Cutan Med Surg"},{"key":"2025081809374412200_ljaf156-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025081809374412200_ljaf156-B14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.26502\/jbb.2642-91280155","article-title":"Exploring the complexities of atopic dermatitis: pathophysiological mechanisms and therapeutic approaches","volume":"7","author":"Chaudhary","year":"2024","journal-title":"J Biotechnol Biomed"},{"key":"2025081809374412200_ljaf156-B15","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs","volume":"79","author":"M\u00fcller","year":"2024","journal-title":"Allergy"},{"key":"2025081809374412200_ljaf156-B16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11882-024-01145-x","article-title":"Comparison of old and new systemic treatments for moderate to severe atopic dermatitis","volume":"24","author":"Yim","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"2025081809374412200_ljaf156-B17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40257-017-0324-7","article-title":"Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis","volume":"19","author":"Snast","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025081809374412200_ljaf156-B18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14712598.2020.1722998","article-title":"Efficacy of biologics in atopic dermatitis","volume":"20","author":"Wu","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2025081809374412200_ljaf156-B19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025081809374412200_ljaf156-B20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/09546634.2019.1623860","article-title":"Patient and physician preferences for atopic dermatitis injection treatments in Japan","volume":"31","author":"Okubo","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2025081809374412200_ljaf156-B21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025081809374412200_ljaf156-B22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","article-title":"Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025081809374412200_ljaf156-B23","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling \u2013 a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2025081809374412200_ljaf156-B24","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/molecules26164907","article-title":"Recent advances in BTK inhibitors for the treatment of inflammatory and autoimmune diseases","volume":"26","author":"Zhang","year":"2021","journal-title":"Molecules"},{"key":"2025081809374412200_ljaf156-B25","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/all.15261","article-title":"Bruton's tyrosine kinase inhibition \u2013 an emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","author":"Mendes-Bastos","year":"2022","journal-title":"Allergy"},{"key":"2025081809374412200_ljaf156-B26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40521-021-00286-y","article-title":"The use of Bruton's tyrosine kinase inhibitors to treat allergic disorders","volume":"8","author":"Dispenza","year":"2021","journal-title":"Curr Treat Options Allergy"},{"key":"2025081809374412200_ljaf156-B27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study","volume":"185","author":"Murrell","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025081809374412200_ljaf156-B28","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J Immunol"},{"key":"2025081809374412200_ljaf156-B29","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"key":"2025081809374412200_ljaf156-B30","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/jcm11102807","article-title":"Bruton's kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"Robak","year":"2022","journal-title":"J Clin Med"},{"key":"2025081809374412200_ljaf156-B31","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025081809374412200_ljaf156-B32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2025081809374412200_ljaf156-B33","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/cts.13524","article-title":"Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: absorption, metabolism, excretion, and absolute bioavailability in healthy participants","volume":"16","author":"Ucpinar","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2025081809374412200_ljaf156-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2025081809374412200_ljaf156-B35","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","article-title":"Endophenotypic variations of atopic dermatitis by age, race, and ethnicity","volume":"8","author":"Nomura","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025081809374412200_ljaf156-B36","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"2025081809374412200_ljaf156-B37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025081809374412200_ljaf156-B38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025081809374412200_ljaf156-B39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","article-title":"Efficacy and safety of abrocitinib in patients with severe and\/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025081809374412200_ljaf156-B40","doi-asserted-by":"crossref","first-page":"2190430","DOI":"10.1080\/09546634.2023.2190430","article-title":"Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial","volume":"34","author":"Thyssen","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2025081809374412200_ljaf156-B41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2021.07.078","article-title":"Itch: pathogenesis and treatment","volume":"86","author":"Sutaria","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025081809374412200_ljaf156-B42","first-page":"AB373","article-title":"Efficacy and safety of rilzabrutinib in patients with chronic spontaneous urticaria: 12-week results from the RILECSU phase 2 dose-ranging study","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2025081809374412200_ljaf156-B43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2019.06.016","article-title":"Pruritus in allergy and immunology","volume":"144","author":"Yang","year":"2019","journal-title":"J Allergy Clin Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf156\/63049915\/ljaf156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/3\/424\/63049915\/ljaf156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/3\/424\/63049915\/ljaf156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T13:37:57Z","timestamp":1755524277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/3\/424\/8124468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,3]]},"published-print":{"date-parts":[[2025,8,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf156","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,3]]}}}